"Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A general term for various neoplastic diseases of the lymphoid tissue.
| Descriptor ID |
D008223
|
| MeSH Number(s) |
C04.557.386 C15.604.515.569 C20.683.515.761
|
| Concept/Terms |
Lymphoma- Lymphoma
- Lymphomas
- Sarcoma, Germinoblastic
- Germinoblastic Sarcoma
- Germinoblastic Sarcomas
- Sarcomas, Germinoblastic
- Reticulolymphosarcoma
- Reticulolymphosarcomas
- Germinoblastoma
- Germinoblastomas
- Lymphoma, Malignant
- Lymphomas, Malignant
- Malignant Lymphoma
- Malignant Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma".
This graph shows the total number of publications written about "Lymphoma" by people in this website by year, and whether "Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 7 | 18 |
| 1995 | 12 | 4 | 16 |
| 1996 | 12 | 6 | 18 |
| 1997 | 5 | 9 | 14 |
| 1998 | 6 | 4 | 10 |
| 1999 | 8 | 6 | 14 |
| 2000 | 14 | 7 | 21 |
| 2001 | 8 | 3 | 11 |
| 2002 | 13 | 9 | 22 |
| 2003 | 14 | 5 | 19 |
| 2004 | 16 | 3 | 19 |
| 2005 | 16 | 8 | 24 |
| 2006 | 14 | 6 | 20 |
| 2007 | 15 | 7 | 22 |
| 2008 | 11 | 4 | 15 |
| 2009 | 18 | 5 | 23 |
| 2010 | 15 | 5 | 20 |
| 2011 | 19 | 7 | 26 |
| 2012 | 16 | 3 | 19 |
| 2013 | 16 | 1 | 17 |
| 2014 | 22 | 7 | 29 |
| 2015 | 30 | 0 | 30 |
| 2016 | 28 | 3 | 31 |
| 2017 | 27 | 4 | 31 |
| 2018 | 14 | 2 | 16 |
| 2019 | 17 | 5 | 22 |
| 2020 | 16 | 1 | 17 |
| 2021 | 23 | 1 | 24 |
| 2022 | 18 | 1 | 19 |
| 2023 | 22 | 1 | 23 |
| 2024 | 9 | 2 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma" by people in Profiles.
-
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. J Natl Cancer Inst. 2024 Nov 01; 116(11):1721-1729.
-
Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups. Lancet Haematol. 2024 Dec; 11(12):e951-e958.
-
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone Marrow Transplant. 2024 Dec; 59(12):1754-1762.
-
Minimal residual disease detection in lymphoma: methods, procedures and clinical significance. Front Immunol. 2024; 15:1430070.
-
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024 07 09; 8(13):3360-3371.
-
Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Mol Ther. 2024 Oct 02; 32(10):3504-3521.
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
-
Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study. Am J Hematol. 2024 07; 99(7):1230-1239.
-
Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma. Lancet. 2024 Apr 06; 403(10434):1372-1373.
-
Systematic review of mortality and survival rates for APDS. Clin Exp Med. 2024 Jan 27; 24(1):17.